UMR 6186, Marseille
Effects of chronic L-DOPA treatment elucidated
Published in Elder Law Weekly, December 1st, 2004
"There is growing experimental evidence for the implication of glutamate-mediated mechanisms both in the pathophysiology of Parkinson disease and in the development of dyskinesias with long-term administration of L-3,4-dihydroxyphenylalanine (L-DOPA)," scientists in France explained. "However, the impact of this treatment on glutamate transmission in the basal ganglia has been poorly investigated."
In a recent study, S. Robelet and coauthors at UMR 6186 in Marseille "examined the effects of 6-hydroxydopamine-induced...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
Source: Elder Law Weekly (2004-12-01)
More Articles from Elder Law Weekly
- Centocor
New reimbursement policy increases patient access to REMICADE - Neurobiological Technologies, Inc.
Biotechnology company receives royalty payment for Alzheimer product - Novartis
Femara gets U.S. FDA nod as post-tamoxifen treatment for early breast cancer - Pontificia Universidad Catolica de Chile
Beta-sheet breaker peptide prevents Alzheimer's memory impairments - Adolor Corporation
Biopharmaceutical company reports loss of $0.22 per share - AgResearch Ltd
ELISA for detection of yessotoxin and its analogs developed - More from this issue of Elder Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
